TargetBeta
PTGIR
prostaglandin I2 receptor · also IP · Prostaglandin receptors
2 programs in company-led studies act on PTGIR, from 2 companies: 0 in phase 3, 2 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| treprostinilrule | United Therapeutics | phase 4 | 739 running | – | ChEMBL |
| selexipagrule | Johnson & Johnson | phase 4 | 233 running | – | ChEMBL |
Conditions their studies are in
- Hypertension, Pulmonary, 2 programs
- Pulmonary Arterial Hypertension, 2 programs
- Scleroderma, Systemic, 2 programs
- Chronic Limb-Threatening Ischemia, 1 program
- Hypertension, 1 program
- Idiopathic Pulmonary Fibrosis, 1 program
- Sarcoidosis, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Jan 31, 2027selexipag · Johnson & Johnson · phase 4 · NCT05179876
- Feb 2027treprostinil · United Therapeutics · phase 4 · NCT07748000
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.